in Europe for Dystrophic Epidermolysis Bullosa
The topical gene therapy candidate KB103 to treat dystrophic epidermolysis bullosa (DEB) has been granted PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA) … KB103 is a gene therapy candidate developed by Krystal Biotech to deliver a functional COL7A1 gene directly to skin cells using a modified and safe herpes simplex virus. Mutations in the COL7A1 gene are the underlying cause of DEB and lead to a defective production of COL7 protein, causing layers of the skin to separate and form blisters … read more